Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Hepcidin antagonists for potential treatments of disorders with hepcidin excess.

Frontiers in pharmacology

Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P.
PMID: 24808863
Front Pharmacol. 2014 Apr 28;5:86. doi: 10.3389/fphar.2014.00086. eCollection 2014.

The discovery of hepcidin clarified the basic mechanism of the control of systemic iron homeostasis. Hepcidin is mainly produced by the liver as a propeptide and processed by furin into the mature active peptide. Hepcidin binds ferroportin, the only...

Cite
Poli M, Asperti M, Ruzzenenti P, et al. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol. 2014;5:86doi: 10.3389/fphar.2014.00086.
Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., & Arosio, P. (2014). Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Frontiers in pharmacology, 586. https://doi.org/10.3389/fphar.2014.00086
Poli, Maura, et al. "Hepcidin antagonists for potential treatments of disorders with hepcidin excess." Frontiers in pharmacology vol. 5 (2014): 86. doi: https://doi.org/10.3389/fphar.2014.00086
Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol. 2014 Apr 28;5:86. doi: 10.3389/fphar.2014.00086. eCollection 2014. PMID: 24808863; PMCID: PMC4009444.
Copy Download .nbib Format: NLM
Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?.

Clinical kidney journal

Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F.
PMID: 27679716
Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 09.

A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as epidemiological and clinical research settings. It is recommended by Kidney Disease: Improving Global Outcomes guidelines in specific populations (anorectic, cirrhotic, obese,...

Cite
Delanaye P, Melsom T, Ebert N, et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. Clin Kidney J. 2016;9(5):700-4doi: 10.1093/ckj/sfw071.
Delanaye, P., Melsom, T., Ebert, N., Bäck, S. E., Mariat, C., Cavalier, E., Björk, J., Christensson, A., Nyman, U., Porrini, E., Remuzzi, G., Ruggenenti, P., Schaeffner, E., Soveri, I., Sterner, G., Eriksen, B. O., & Gaspari, F. (2016). Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. Clinical kidney journal, 9(5), 700-4. https://doi.org/10.1093/ckj/sfw071
Delanaye, Pierre, et al. "Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?." Clinical kidney journal vol. 9,5 (2016): 700-4. doi: https://doi.org/10.1093/ckj/sfw071
Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 09. PMID: 27679716; PMCID: PMC5036903.
Copy Download .nbib Format: NLM
Mechanisms of progression of chronic renal disease.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

Pisoni R, Aros C, Ruggenenti P, Remuzzi G.
PMID: 18209421
Saudi J Kidney Dis Transpl. 2002 Jul-Sep;13(3):250-6.

Many patients with proteinuric chronic nephropathies progress relentlessly to end-stage renal failure (ESRF). Research in animal and human models has helped to identify the mechanisms involved in this progression and to indicate effective intervention. We review the main factors...

Cite
Pisoni R, Aros C, Ruggenenti P, et al. Mechanisms of progression of chronic renal disease. Saudi J Kidney Dis Transpl. 2002;13(3):250-6
Pisoni, R., Aros, C., Ruggenenti, P., & Remuzzi, G. (2002). Mechanisms of progression of chronic renal disease. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 13(3), 250-6.
Pisoni, Roberto, et al. "Mechanisms of progression of chronic renal disease." Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia vol. 13,3 (2002): 250-6.
Pisoni R, Aros C, Ruggenenti P, Remuzzi G. Mechanisms of progression of chronic renal disease. Saudi J Kidney Dis Transpl. 2002 Jul-Sep;13(3):250-6. PMID: 18209421.
Copy Download .nbib Format: NLM
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation.

Journal of transplantation

Gennarini A, Cravedi P, Marasà M, Perna A, Rota G, Bontempelli M, Sandrini S, Remuzzi G, Ruggenenti P.
PMID: 22685630
J Transplant. 2012;2012:426042. doi: 10.1155/2012/426042. Epub 2012 May 20.

Dual induction with low doses of rabbit anti-human thymoglobulin (RATG) and basiliximab effectively and safely prevented allograft rejection in high-risk renal transplant recipients. To assess whether treatment timing affects efficacy and tolerability, in this single-center, matched-cohort study, we compared...

Cite
Gennarini A, Cravedi P, Marasà M, et al. Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant. 2012;2012:426042doi: 10.1155/2012/426042.
Gennarini, A., Cravedi, P., Marasà, M., Perna, A., Rota, G., Bontempelli, M., Sandrini, S., Remuzzi, G., & Ruggenenti, P. (2012). Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. Journal of transplantation, 2012426042. https://doi.org/10.1155/2012/426042
Gennarini, Alessia, et al. "Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation." Journal of transplantation vol. 2012 (2012): 426042. doi: https://doi.org/10.1155/2012/426042
Gennarini A, Cravedi P, Marasà M, Perna A, Rota G, Bontempelli M, Sandrini S, Remuzzi G, Ruggenenti P. Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant. 2012;2012:426042. doi: 10.1155/2012/426042. Epub 2012 May 20. PMID: 22685630; PMCID: PMC3364007.
Copy Download .nbib Format: NLM
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Frontiers in genetics

Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P.
PMID: 31428128
Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019.

Complement activation has been increasingly implicated in the pathogenesis of type 2 diabetes and its chronic complications. It is unknown whether complement factor H (CFH) genetic variants, which have been previously associated with complement-mediated organ damage likely due to...

Cite
Valoti E, Noris M, Perna A, et al. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Front Genet. 2019;10:681doi: 10.3389/fgene.2019.00681.
Valoti, E., Noris, M., Perna, A., Rurali, E., Gherardi, G., Breno, M., Parvanova Ilieva, A., Petrov Iliev, I., Bossi, A., Trevisan, R., Dodesini, A. R., Ferrari, S., Stucchi, N., Benigni, A., Remuzzi, G., & Ruggenenti, P. (2019). Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in genetics, 10681. https://doi.org/10.3389/fgene.2019.00681
Valoti, Elisabetta, et al. "Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes." Frontiers in genetics vol. 10 (2019): 681. doi: https://doi.org/10.3389/fgene.2019.00681
Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019. PMID: 31428128; PMCID: PMC6689971.
Copy Download .nbib Format: NLM
Understanding the nature of renal disease progression.

Kidney international

Remuzzi G, Ruggenenti P, Benigni A.
PMID: 8995712
Kidney Int. 1997 Jan;51(1):2-15. doi: 10.1038/ki.1997.2.
Free Article

Animal and human proteinuric glomerulopathies evolve to terminal renal failure by a process leading to progressive parenchymal damage, which appears to be relatively independent of the initial insult. Despite the fact that the mechanism(s) leading to renal disease progression...

Cite
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51(1):2-15doi: 10.1038/ki.1997.2.
Remuzzi, G., Ruggenenti, P., & Benigni, A. (1997). Understanding the nature of renal disease progression. Kidney international, 51(1), 2-15. https://doi.org/10.1038/ki.1997.2
Remuzzi, G, et al. "Understanding the nature of renal disease progression." Kidney international vol. 51,1 (1997): 2-15. doi: https://doi.org/10.1038/ki.1997.2
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997 Jan;51(1):2-15. doi: 10.1038/ki.1997.2. PMID: 8995712.
Copy Download .nbib Format: NLM
Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint .

EClinicalMedicine

Ruggenenti P, Caruso MR, Cortinovis M, Perna A, Peracchi T, Giuliano GA, Rota S, Brambilla P, Invernici G, Villa D, Diadei O, Trillini M, Natali G, Remuzzi G.
PMID: 34977512
EClinicalMedicine. 2021 Dec 14;43:101227. doi: 10.1016/j.eclinm.2021.101227. eCollection 2022 Jan.

BACKGROUND: Standard diet with normal calcium and reduced animal proteins and salt content reduces stone recurrence in calcium oxalate nephrolithiasis. Whether lemon juice supplementation further reduces recurrence rate is unknown.METHODS: In this single-centre, prospective, randomised, open, blinded endpoint trial...

Cite
Ruggenenti P, Caruso MR, Cortinovis M, et al. Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint . EClinicalMedicine. 2021;43:101227doi: 10.1016/j.eclinm.2021.101227.
Ruggenenti, P., Caruso, M. R., Cortinovis, M., Perna, A., Peracchi, T., Giuliano, G. A., Rota, S., Brambilla, P., Invernici, G., Villa, D., Diadei, O., Trillini, M., Natali, G., & Remuzzi, G. (2022). Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint . EClinicalMedicine, 43101227. https://doi.org/10.1016/j.eclinm.2021.101227
Ruggenenti, Piero, et al. "Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint ." EClinicalMedicine vol. 43 (2022): 101227. doi: https://doi.org/10.1016/j.eclinm.2021.101227
Ruggenenti P, Caruso MR, Cortinovis M, Perna A, Peracchi T, Giuliano GA, Rota S, Brambilla P, Invernici G, Villa D, Diadei O, Trillini M, Natali G, Remuzzi G. Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint . EClinicalMedicine. 2021 Dec 14;43:101227. doi: 10.1016/j.eclinm.2021.101227. eCollection 2022 Jan. PMID: 34977512; PMCID: PMC8683665.
Copy Download .nbib Format: NLM
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.

PloS one

Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G.
PMID: 34928990
PLoS One. 2021 Dec 20;16(12):e0261113. doi: 10.1371/journal.pone.0261113. eCollection 2021.

BACKGROUND: Complement activation contributes to lung dysfunction in coronavirus disease 2019 (COVID-19). We assessed whether C5 blockade with eculizumab could improve disease outcome.METHODS: In this single-centre, academic, unblinded study two 900 mg eculizumab doses were added-on standard therapy in...

Cite
Ruggenenti P, Di Marco F, Cortinovis M, et al. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One. 2021;16(12):e0261113doi: 10.1371/journal.pone.0261113.
Ruggenenti, P., Di Marco, F., Cortinovis, M., Lorini, L., Sala, S., Novelli, L., Raimondi, F., Gastoldi, S., Galbusera, M., Donadelli, R., Mele, C., Piras, R., Noris, M., Portalupi, V., Cappelletti, L., Carrara, C., Tomatis, F., Bernardi, S., Perna, A., Peracchi, T., Diadei, O., Benigni, A., & Remuzzi, G. (2021). Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PloS one, 16(12), e0261113. https://doi.org/10.1371/journal.pone.0261113
Ruggenenti, Piero, et al. "Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study." PloS one vol. 16,12 (2021): e0261113. doi: https://doi.org/10.1371/journal.pone.0261113
Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One. 2021 Dec 20;16(12):e0261113. doi: 10.1371/journal.pone.0261113. eCollection 2021. PMID: 34928990; PMCID: PMC8687582.
Copy Download .nbib Format: NLM
Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study.

Nephron

Bikbov B, Ruggenenti P, Perna A, Perico N, Gotti E, Plati A, Gaspari F, Carrara F, Gambara V, Peracchi T, Rossini G, Rota G, Lacanna F, Amaduzzi A, Colledan M, Remuzzi G.
PMID: 34130292
Nephron. 2021;145(6):642-652. doi: 10.1159/000516534. Epub 2021 Jun 15.

INTRODUCTION: To safely expand the donor pool, we introduced a strategy of biopsy-guided selection and allocation to single or dual transplantation of kidneys from donors >60 years old or with hypertension, diabetes, and/or proteinuria (older/marginal donors). Here, we evaluated...

Cite
Bikbov B, Ruggenenti P, Perna A, et al. Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study. Nephron. 2021;145(6):642-652doi: 10.1159/000516534.
Bikbov, B., Ruggenenti, P., Perna, A., Perico, N., Gotti, E., Plati, A., Gaspari, F., Carrara, F., Gambara, V., Peracchi, T., Rossini, G., Rota, G., Lacanna, F., Amaduzzi, A., Colledan, M., & Remuzzi, G. (2021). Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study. Nephron, 145(6), 642-652. https://doi.org/10.1159/000516534
Bikbov, Boris, et al. "Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study." Nephron vol. 145,6 (2021): 642-652. doi: https://doi.org/10.1159/000516534
Bikbov B, Ruggenenti P, Perna A, Perico N, Gotti E, Plati A, Gaspari F, Carrara F, Gambara V, Peracchi T, Rossini G, Rota G, Lacanna F, Amaduzzi A, Colledan M, Remuzzi G. Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study. Nephron. 2021;145(6):642-652. doi: 10.1159/000516534. Epub 2021 Jun 15. PMID: 34130292.
Copy Download .nbib Format: NLM
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients.

Data in brief

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P.
PMID: 30533454
Data Brief. 2018 Nov 14;21:2075-2081. doi: 10.1016/j.dib.2018.11.041. eCollection 2018 Dec.

In this article, we report anthropometric, clinical and laboratory data from Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with mild to moderate renal dysfunction and normal LV ejection fraction and from age- and sex-matched healthy controls and renal controls....

Cite
Spinelli L, Pisani A, Giugliano G, et al. Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. Data Brief. 2018;21:2075-2081doi: 10.1016/j.dib.2018.11.041.
Spinelli, L., Pisani, A., Giugliano, G., Trimarco, B., Riccio, E., Visciano, B., Remuzzi, G., & Ruggenenti, P. (2018). Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. Data in brief, 212075-2081. https://doi.org/10.1016/j.dib.2018.11.041
Spinelli, Letizia, et al. "Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients." Data in brief vol. 21 (2018): 2075-2081. doi: https://doi.org/10.1016/j.dib.2018.11.041
Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P. Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. Data Brief. 2018 Nov 14;21:2075-2081. doi: 10.1016/j.dib.2018.11.041. eCollection 2018 Dec. PMID: 30533454; PMCID: PMC6262192.
Copy Download .nbib Format: NLM
A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study.

EClinicalMedicine

Suter F, Consolaro E, Pedroni S, Moroni C, Pastò E, Paganini MV, Pravettoni G, Cantarelli U, Rubis N, Perico N, Perna A, Peracchi T, Ruggenenti P, Remuzzi G.
PMID: 34127959
EClinicalMedicine. 2021 Jul;37:100941. doi: 10.1016/j.eclinm.2021.100941. Epub 2021 Jun 09.

BACKGROUND: Effective home treatment algorithms implemented based on a pathophysiologic and pharmacologic rationale to accelerate recovery and prevent hospitalisation of patients with early coronavirus disease 2019 (COVID-19) would have major implications for patients and health system.METHODS: This academic, matched-cohort...

Cite
Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. EClinicalMedicine. 2021;37:100941doi: 10.1016/j.eclinm.2021.100941.
Suter, F., Consolaro, E., Pedroni, S., Moroni, C., Pastò, E., Paganini, M. V., Pravettoni, G., Cantarelli, U., Rubis, N., Perico, N., Perna, A., Peracchi, T., Ruggenenti, P., & Remuzzi, G. (2021). A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. EClinicalMedicine, 37100941. https://doi.org/10.1016/j.eclinm.2021.100941
Suter, Fredy, et al. "A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study." EClinicalMedicine vol. 37 (2021): 100941. doi: https://doi.org/10.1016/j.eclinm.2021.100941
Suter F, Consolaro E, Pedroni S, Moroni C, Pastò E, Paganini MV, Pravettoni G, Cantarelli U, Rubis N, Perico N, Perna A, Peracchi T, Ruggenenti P, Remuzzi G. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. EClinicalMedicine. 2021 Jul;37:100941. doi: 10.1016/j.eclinm.2021.100941. Epub 2021 Jun 09. PMID: 34127959; PMCID: PMC8189543.
Copy Download .nbib Format: NLM
Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report.

Kidney medicine

Caroli A, Remuzzi A, Ruggiero B, Carrara C, Rizzo P, Brambilla P, Ruggenenti P, Remuzzi G.
PMID: 33319205
Kidney Med. 2020 Oct 23;2(6):804-809. doi: 10.1016/j.xkme.2020.07.008. eCollection 2020.

In recent years, kidney functional magnetic resonance imaging (MRI) has seen great advances, with several cross-sectional studies demonstrating correlations between MRI biomarkers and glomerular filtration rate. However, the potential of MRI to monitor response to therapy in kidney disease...

Cite
Caroli A, Remuzzi A, Ruggiero B, et al. Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Med. 2020;2(6):804-809doi: 10.1016/j.xkme.2020.07.008.
Caroli, A., Remuzzi, A., Ruggiero, B., Carrara, C., Rizzo, P., Brambilla, P., Ruggenenti, P., & Remuzzi, G. (2020). Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney medicine, 2(6), 804-809. https://doi.org/10.1016/j.xkme.2020.07.008
Caroli, Anna, et al. "Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report." Kidney medicine vol. 2,6 (2020): 804-809. doi: https://doi.org/10.1016/j.xkme.2020.07.008
Caroli A, Remuzzi A, Ruggiero B, Carrara C, Rizzo P, Brambilla P, Ruggenenti P, Remuzzi G. Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Med. 2020 Oct 23;2(6):804-809. doi: 10.1016/j.xkme.2020.07.008. eCollection 2020. PMID: 33319205; PMCID: PMC7729249.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries